Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.
Weijia XieJiaxin LiHao DuJian XiaPublished in: Arthritis research & therapy (2023)
PCSK9 inhibitor significantly reduced the risk of SLE but increased the risk of asthma and CD. In contrast, HMGCR inhibitor may be a risk factor for RA, asthma, and CD.